Solid dispersions: Revival with greater possibilities and applications in oral drug delivery

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 20, Issue 2-3, 2003, Pages 215-247

  Sethia, Sundeep ^a   Squillante, Emilio ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Carriers; Coprecipitates; Drug delivery systems; Solid dispersions; Supercritical fluids

Indexed keywords

1 VINYL 2 PYRROLIDINONE; CARBAMAZEPINE; COLLAGEN; CREMOPHOR; DRUG CARRIER; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETONOGESTREL; EUDRAGIT; FENOFIBRATE; GELUCIRE; HYDROXYMETHYLCELLULOSE; INDOMETACIN; ITRACONAZOLE; LACTOSE; MACROGOL 4000; MACROGOL 6000; MANNITOL; NIFEDIPINE; OXAZEPAM; PARACETAMOL; POVIDONE; PROGESTERONE; RIBOFLAVIN; SULFATHIAZOLE; TESTOSTERONE; TOCOFERSOLAN; TRIAMTERENE; TROGLITAZONE; UNINDEXED DRUG; VINYL ACETATE; VITAMIN E TPGS;

CONTROLLED DRUG RELEASE; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG SOLUBILITY; HUMAN; NONHUMAN; REPRODUCIBILITY; REVIEW;

ADMINISTRATION, ORAL; DRUG DELIVERY SYSTEMS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0141997759     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23.40     Document Type: Review

References (154)

1. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000; 50:3-12.
2. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19:930-34.
3. Nernst W. Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. Zeitschrift f Physik Chemie 1904; 47:52-55.
4. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997; 25:103-28.
5. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci 2000; 89:429-42.
6. Khoo SM, Porter CJH, Charman WN. The formulation of halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment. Int J Pharm 2000; 205:65-78.
7. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16:1550-56.
8. Nerurkar NM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 1996; 13:528-34.
9. Charman WN. Lipids, lipophilic drugs and oral drug delivery-some emerging concepts. J Pharm Sci 2000; 89:967-78.
10. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000; 50:47-60.
11. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersions. J Pharm Sci 1971; 60:1281-302.
12. Bates TR. Dissolution characteristics of reserpine-polyvinylpyrrolidone co-precipitates. J Pharm Pharmacol 1969; 21:710-12.
13. Corrigan OI, Crean AM. Comparative physicochemical properties of hydrocortisone-PVP composites prepared using supercritical carbon dioxide by the GAS anti-solvent recrystallization process, by coprecipitation and by spray drying. Int J Pharm 2002; 245:75-82.
14. Sekikawa H, Naganuma R, Fujiwara J, Nakano M, Arita T. Dissolution behavior and gastrointestinal absorption of tolbutamide in tolbutamide-polyvinylpyrrolidone coprecipitates. Chem Pharm Bull 1979; 27:31-37.
15. Simonelli AP, Mehta SC, Higuchi WI. Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J Pharm Sci 1969; 58:538-49.
16. Sertsou G, Butler J, Scott A, Hempenstall J, Rades T. Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation. Int J Pharm 2002; 245:99-108.
17. Khan MA, Shojaei AH, Karnachi AA, Reddy IK. Comparative evaluation of controlled-release solid oral dosage forms prepared with solid dispersions and coprecipitates. Pharm Technol 1999; May:58-74.
18. Khan MA, Karnachi AA, Agarwal V, Vaithiyalingam SR, Nazzal S, Reddy IK. Stability characterization of controlled release coprecipitates and solid dispersions. J Control Release 2000; 63:1-6.
19. Najib N, Suleiman M. Characterisation of a diffusinal polyethylene glycol solid dispersion system. Int J Pharm 1989;51:225-32.
20. Kaur R, Grant DJW. Solid dispersions of drugs in polyoxyethylene 40 stearate: dissolution rates and physicochemical interactions. J Pharm Pharmacol 1979; 31 (Suppl) 48P.
21. Jafari MR, Danti AG, Ahmed I. Comparison of polyethylene glycol, polyvinylpyrrolidone and urea as excipients for solid dispersion systems of miconazole nitrate. Int J Pharm 1988; 48:207-15.
22. Craig DQM, Newton JM. Characterization of polyethylene glycol solid dispersions using differential scanning calorimetry and solution calorimetry. Int J Pharm 1991; 76:17-24.
23. Lloyd GR, Craig DQM, Smith A. An investigation into the production of paracetamol solid dispersions in PEG 4000 using hot stage differential interference contrast microscopy. Int J Pharm 1997; 158:39-46.
24. Ford JL. The current status of solid dispersions. Pharm Acta Helv 1986; 61:69-88.
25. Sekiguchi K, Obi N. Studies on absorption of eutectic mixtures. I. A comparison of the behavior of eutectic mixtures of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 1961; 9:866-72.
26. Law D, Wang W, Schmitt EA, Krill SL, Fort JJ. Properties of rapidly dissolving eutectic mixtures of poly (ethylene glycol) and fenofibrate: the eutectic microstructure. J Pharm Sci 2002; 92:505-15.
27. Chiou WL, Riegelman S. Increased dissolution rates of water-insoluble cardiac glycosides and steroids via solid dispersions in polyethylene glycol 6000. J Pharm Sci 1971; 60:1569-71.
28. Allen LV, Yanchick VA, Maness DD. Dissolution rates of corticosteroids utilizing sugar glass dispersions. J Pharm Sci 1977; 66:494-97.
29. Verheyen S, Blaton N, Kinget R, Van den Mooter G. Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int J Pharm 2002; 249:45-58.
30. Lin CW, Cham TM. Effect of particle size on the available surface area of nifedipine from nifedipine-poly(ethylene glycol) 6000 solid dispersions. Int J Pharm 1996; 127:261-72.
31. Vippagunta SR, Maul KA, Tallavajhala S, Grant DJW. Solid-state characterization of nifedipine solid dispersions. Int J Pharm 2002; 236:111-23.
32. Kapsi SG, Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm 2001; 229:193-203.
33. Kanig JL. Properties of fused mannitol in compressed tablets. J Pharm Sci 1964; 188-92.
34. Dittgen M, Fricke S, Gerecke H, Osterwald H. The use of sugar and sugar alcohols to enhance the solubility and the bioavailability of drugs. Eur J Pharm Biopharm 1994; 40 (Suppl):14S.
35. Dittgen M, Fricke S, Gerecke H, Osterwald H. Hot spin mixing - a new technology to manufacture solid dispersions, part 1: testosterone. Pharmazie 1995; 50:225-26.
36. Dittgen M, Fricke S, Gerecke H, Osterwald H. Hot spin mixing - a new technology to manufacture solid dispersions, part 3: progesterone. Pharmazie 1995; 50:507-08.
37. El-Banna HM, Daabis NA, Mortada LM, Abd-Elfattah S. Physicochemical study of drug binary systems. Part 3: Tolbutamide-urea and tolbutamide-mannitol systems. Pharmazie 1975; 30:788-92.
38. Tachibana T, Nakamura N. A method for preparing an aqueous colloidal dispersion of organic materials by using water-soluble polymers: dispersion of beta-carotene by polyvinylpyrrolidone. Kolloid-Z Polym 1965; 203:130-33.
39. Fernandez M, Rodriguez IC, Margarit MV, Cerezo A. Characterization of solid dispersions of piroxicam/poly(ethylene glycol) 4000. Int J Pharm 1992; 84:197-202.
40. Van den Mooter G, Augustijns P, Blaton N, Kinget R. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm 1998; 164:67-80.
41. El-Zein H, Riad L, El-Bary AA. Enhancement of carbamazepine dissolution: in vitro and in vivo evaluation. Int J Pharm 1998; 168:209-20.
42. Shin SC, Kim J. Physicochemical characterization of solid dispersion of furosemide with TPGS. Int J Pharm 2003; 251:79-84.
43. Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, Kinget R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 2001; 12:261-69.
44. Yoo SD, Lee SH, Kang E, Jun H, Jung JY, Park JW, Lee KH. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug Dev Ind Pharm 2000; 26:27-34.
45. Betageri GV, Makarla KR. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int J Pharm 1995; 126:155-60.
46. Nabekura T, Ito Y, Cai H, Terao M, Hori R. Preparation and in vivo absorption studies of disulfiram solid dispersion. Biol Pharm Bull 2000; 23:616-20.
47. Arias MJ, Ginés JM, Moyano JR, Pérez-Martínez JI, Rabasco AM. Influence of the preparation method of solid dispersions on their dissolution rate: study of triamterene-D-mannitol system. Int J Pharm 1995; 123:25-31.
48. Jachowicz R, Nürnberg E, Hoppe R. Solid dispersions of oxazepam. Int J Pharm 1993; 99:321-25.
49. Cilurzo F, Minghetti P, Casiraghi A, Montanari L. Characterization of nifedipine solid dispersions. Int J Pharm 2002; 242:313-17.
50. Jung JY, Yoo SD, Lee SH, Kim KH, Yoon DS, Lee KH. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm 1999; 187:209-18.
51. Jung JY, Kim KH, Lee SH, Hong JW, Park JW, Lee KH. Method and composition of an oral preparation of itraconazole. US Patent 6485743, 2002.
52. Wells J, Rubinstein M, Walter V. In situ fusion and granulation of a chlorpropamide-urea solid solution for compressed tablets. J Pharm Pharmacol 1975; 27 (Suppl):56P.
53. Chiou WL. Pharmaceutical applications of solid dispersion systems: X-ray diffraction and aqueous solubility studies on griseofulvin-poly(ethylene glycol) 6000 systems. J Pharm Sci 1977; 66:989-91.
54. Beten DB, Amighi K, Moës AJ. Preparation of controlled-release coevaporates of dipyridamole by loading neutral pellets in a fluidized-bed coating system. Pharm Res 1995; 12:1269-72.
55. Ho HO, Su HL, Tsai T, Sheu MT. The preparation and characterization of solid dispersions on pellets using a fluidized-bed system. Int J Pharm 1996; 139:223-29.
56. Gilis PA, De Conde V, Vandecruys R. Beads having a core coated with an antifungal and a polymer. US Patent 5633015, 1997.
57. Kennedy JP, Niebergall PJ. Development and optimization of a solid dispersion hot-melt fluid bed coating method. Pharm Dev Technol 1996; 1:51-62.
58. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm 2002; 54:107-17.
59. Vervaet C, Baert L, Remon JP. Extrusion-spheronisation - a literature review. Int J Pharm 1995; 116:131-46.
60. Doelker M, Adel El-Egakey M, Soliva M, Speiser P. Hot extruded dosage forms. Pharm Acta Helv 1971; 46:31-52.
61. Nakamichi K, Yasuura H, Kukui H, Oka M, Izumi S, Andou T, Shimizu N, Ushimaru K. New preparation method of solid dispersion by twin screw extruder. Pharm Tech Jpn 1996; 12:715-29.
62. Perissutti B, Newton JM, Podczeck F, Rubessa F. Preparation of extruded carbamazepine and PEG 4000 as a potential rapid release dosage form. Eur J Pharm Biopharm 2002; 53:125-32.
63. Hülsmann S, Backensfeld T, Keitel S, Bodmeier R. Melt extrusion - an alternative method for enhancing the dissolution rate of 17β-estradiol hemihydrate. Eur J Pharm Biopharm 2000; 49:237-42.
64. Zeidler J, Neumann J, Liepold B, Rosenberg J, Berndl G, Vollgraf C. Fast-acting analgesic. US Patent 6322816, 2001.
65. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster ME. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part I. Int J Pharm 2003; 251:165-74.
66. Verreck G, Baert L, Peeters J, Brewster M. Improving aqueous solubility and bioavailability for itraconazole by solid dispersion approach. AAPS Pharm Sci 2001; 3:M2157.
67. Baert L, Thone D, Verreck G. Antifungal compositions with improved bioavailability. World Patent 9744014, 1997.
68. Walker SE, Ganley JA, Bedford K, Eaves T. The filling of molten and thixotropic formulations into hard gelatin capsules. J Pharm Pharmacol 1980; 32:389-93.
69. Serajuddin ATM, Sheen PC, Mufson D, Bernstein DF, Augustine MA. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J Pharm Sci 1988; 77:414-17.
70. Serajuddin ATM, Sheen PC, Mufson D, Bernstein DF, Augustine MA. Physicochemical basis of increased bioavailability of a poorly water-soluble drug following oral administration as organic solutions. J Pharm Sci 1988; 77:325-29.
71. Serajuddin ATM, Sheen PC, Augustine MA. Improved dissolution of a poorly water-soluble drug from solid dispersions in poly(ethylene glycol):polysorbate 80 mixtures. J Pharm Sci 1990; 79:463-64.
72. Law SL, Lo WY, Lin FM, Chang CH. Dissolution and absorption of nifedipine in poly(ethylene glycol) solid dispersion containing phosphatidylcholine. Int J Pharm 1992; 84:161-66.
73. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999; 88:1058-66.
74. Wiley GJ, Ullah I, Agharkar SN. Development of a semiautomatic system for R&D and clinical use for liquid-filled hard gelatin encapsulation. Pharm Technol 1995; May:72-76.
75. Reneker DH, Chun I. Nanometre diameter of polymer, produced by electrospinning. Nanotechnology 1996; 7:216-23.
76. Doshi J, Reneker DH. Electrospinning process and applications of electrospun fibers. J Electrostatics 1995; 35:151-60.
77. Kenawy ER, Bowlin GL, Mansfield K, Layman J, Simpson DG, Sanders EH, Wnek GE. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release 2002; 81:57-64.
78. Ignatious F, Baldoni JM. Electrospun pharmaceutical compositions. World Patent 0154667, 2001.
79. Deitzel JM, Kleinmeyer J, Harris D, BeckTan NC.The effect of processing variables on the morphology of electrospun nanofibers and textiles. Polymers 2001; 42:261-72.
80. Verreck G, Chun I, Peeters J, Rosenblatt J, Brewster ME. Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm Res 2003; 20:810-17.
81. Subramaniam B, Rajewski RA, Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 1997; 86:885-90.
82. McHugh MA, Krukonis VJ. Supercritical Fluid Extraction: Principles and Practice, 2 ed. Newton MA: Butterworth-Heinemann, 1994.
83. Sunkara G, Kompella UB. Drug delivery applications of supercritical fluid technology. Drug Deliv Technol 2002;2(1):44-50.
84. Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carrier Syst 2001; 18:173-99.
85. Palakodaty S, York P. Phase behavioral effects on particle formation processes using supercritical fluids. Pharm Res 1999; 16:976-85.
86. Beach S, Latham D, Sidgwick C, Hanna M, York P. Control of the physical form of salmeterol xinafoate. Organic Proc Res Devel 1999; 3:370-76.
87. Ye C. Enhanced dissolution of relatively insoluble drugs from small particles and solid dispersions formed from supercritical solutions. Ph.D. thesis, Ohio State University, 2000.
88. Liu G-T, Nagahama K. Solubility and RESS experiments of solid solution in supercritical carbon dioxide. J Chem Eng Jpn 1997; 30, 293-301.
89. Hanna M, York P. Method and apparatus for the formation of particles. World Patent 9501221, 1995.
90. Juppo AM, Boiddier C, Khoo C. Evaluation of solid dispersion particles prepared with SEDS. Int J Pharm 2003; 250:385-401.
91. York P, Wilkins SA, Storey RA, Walker SE, Harland RS. Coformulation methods and their products. World Patent 0115664, 2001.
92. 2. Int J Pharm 1997; 148:123-30.
93. Kerc J, Srcic S, Knez Z, Sencar-Bozic P. Micronization of drugs using supercritical carbon dioxide. Int J Pharm 1999; 182:33-39.
94. Gallagher PM, Coffey MP, Krukonis VJ, Klasutis N. Gas antisolvent recrystallization: a new process to recrystallize compounds in supercritical fluids. Am Chem Soc Symp Ser 1989; 406:334-54.
95. Moneghini M, Kikic I, Voinovich D, Perissutti B, Filipovic-Grcic J. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization, and in vitro dissolution. Int J Pharm 2001; 222:129-38.
96. Sethia S, Squillante E. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J Pharm Sci 2002; 91:1948-57.
97. Sethia S, Squillante E. In vitro-in vivo evaluation of supercritical processed solid dispersions: permeability and viability assessment in Caco-2 cells. Pharm Res. (In press.)
98. Berens, AR, Huvard GS, Korsmeyer RW, Kunig RW. Application of compressed carbon dioxide in the incorporation of additives into polymers. J Appl Polym Sci 1992; 46:231-42.
99. Kazarian SG, Martirosyan GG. Spectroscopy of polymer/drug formulations processed with supercritical fluids: in situ ATR-IR and Raman study of impregnation of ibuprofen into PVP. Int J Pharm 2002; 232:81-90.
100. 2-swollen poly(methyl methacrylate) films. AIChE J 1997; 43:1838-48.
101. Squillante E, Mehta KA. Extended-release chlorpheniramine maleate from polymethacrylate solid dispersions by supercritical fluid processing. Drug Deliv Technol 2002; 2(5):58-64.
102. Ford JL, Stewart AF, Dubois JL. The properties of solid dispersions of indomethacin or phenylbutazone in polyethylene glycol. Int J Pharm 1986; 28:11-22.
103. Mura P, Faucci MT, Manderioli A, Bramanti G, Parrini P. Thermal behavior and dissolution properties of naproxen from binary and ternary solid dispersions. Drug Dev Ind Pharm 1999; 25:257-64.
104. Sjökvist E, Nyström C, Aldén M, Caram-Lelham N. Physicochemical aspects of drug release. XIV. The effects of some ionic and non-ionic surfactants on properties of a sparingly soluble drug in solid dispersions. Int J Pharm 1992; 79:123-33.
105. Dubois JL, Ford JL. Similarities in the release rates of different drugs from polyethylene glycol 6000 solid dispersions. J Pharm Pharmacol 1985; 37:494-95.
106. Lo WY, Law SL. Dissolution behavior of griseofulvin solid dispersions using polyethylene glycol, talc, and their combination as dispersion carriers. Drug Dev Ind Pharm 1996; 22:231-36.
107. Walking WD. Povidone. In: Wade A, Weller PJ, editors. Handbook of Pharmaceutical Excipients. Washington DC: The Pharmaceutical Press, 1994.
108. Wu SH, Hopkins WK. Characteristics of d-α-tocopheryl polyethylene glycol 1000 succinate for applications as an absorption enhancer in drug delivery systems. Pharm Technol 1999; October:52-68.
109. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporin pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1996; 59:297-303.
110. Remunan C, Bretal MJ, Nunez A, Jato JLV. Accelerated stability study of sustained-release nifedipine tablets prepared with Gelucire®. Int J Pharm 1992; 80:151-59.
111. Forster A, Hempenstall J, Tucker I, Rades T. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm 2001; 226:147-61.
112. Langer M, Höltje M, Urbanetz NA, Brandt B, Höltje H-D, Lippold BC. Investigations on the predictability of the formation of glassy solid solutions of drugs in sugar alcohols. Int J Pharm 2003; 252:167-79.
113. Breitenbach J, Schrof W, Neumann J. Confocal Raman-spectroscopy: analytical approach to solid dispersions and mapping of drugs. Pharm Res 1999; 16:1109-13.
114. Kaplan SA. Biopharmaceutical considerations in drug formation design and evaluation. Drug Metab Rev 1972; 1:15-34.
115. Hendra PJ. Fourier transform-Raman spectroscopy in pharmaceutical analysis and research. Am Lab 1996; 28:17-24.
116. Broman E, Khoo C, Taylor LS. A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. Int J Pharm 2001; 222:139-151.
117. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002; 231:131-44.
118. Goldberg AH, Gibaldi M, Kanig JL. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures II-experimental evaluation of a eutectic mixture: urea-acetaminophen system. J Pharm Sci 1966; 55:482-87.
119. Stoll RT, Bates TR, Nieforth KA, Swarbrick J. Some physical factors affecting the enhanced blepharototic activity of orally administered reserpine-cholanic acid coprecipitates. J Pharm Sci 1969; 58:1457-59.
120. Kim KH, Jarowski CI. Surface tension lowering and dissolution rate of hydrocortisone from solid solutions of selected n-acyle esters of cholesterol. J Pharm Sci 1977; 66:1536-40.
121. Hilton JE, Summers MP. The effect of wetting agents on the dissolution of indomethacin solid dispersion systems. Int J Pharm 1986; 31:157-64.
122. Usui F, Maeda K, Kusai A, Ikeda M, Nishimura K, Yamamoto K. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int J Pharm 1997; 154:59-66.
123. Ford JL, Rubinstein MH. Phase equilibria and dissolution rates of indomethacin-polyethylene glycol 6000 solid dispersions. Pharm Acta Helv 1978; 53:327-32.
124. Allen DJ, Kwan KC. Determination of the degree of crystallinity in solid-solid equilibria. J Pharm Sci 1969; 58:1190-93.
125. Nair R, Gonen S, Hoag SW. Influence of polyethylene glycol and povidone on the polymorphic transformation and solubility of carbamazepine. Int J Pharm 2002; 240:11-22.
126. Corrigan OI. Mechanisms of dissolution of fast release solid dispersions. Drug Dev Ind Pharm 1985; 11:697-724.
127. Craig DQM, Newton JM. The dissolution of nortriptyline HCl from polyethylene glycol solid dispersions. Int J Pharm 1992; 78:175-82.
128. Higuchi WI. Diffusional models useful in biopharmaceutics. J Pharm Sci 1967; 56:315-24.
129. Sjökvist E, Nyström C. Physicochemical aspects of drug release. VI. Drug dissolution rate from solid particulate dispersions and the importance of carrier and drug particle properties. Int J Pharm 1988; 47:51-66.
130. Sjökvist-Saers E, Craig DQM. An investigation into the mechanisms of dissolution of alkyl p-aminobenzoates from polyethylene glycol solid dispersions. Int J Pharm 1992; 83:211-19.
131. Abbott Laboratories. Abbott to substitute norvir capsules with liquid formulation. Press release, July 29, 1998.
132. Ginés JM, Arias MJ, Moyano JR, Sanchez-Soto PJ. Thermal investigation of crystallization of poly(ethylene glycol)s in solid dispersions containing oxazepam. Int J Pharm 1996; 143:247-53.
133. McGinity JW, Maincent P, Steinfink H. Crystallinity and dissolution of tolbutamide solid dispersions prepared by the melt method. J Pharm Sci 1984; 73:1441-44.
134. Save T, Venkitachalam P. Studies on solid dispersions of nifedipine. Drug Dev Ind Pharm 1992; 18:1663-79.
135. Ford JL, Elliott PNC. The effect of particle size on some in vitro and in vivo properties of indomethacin-poly(ethylene glycol) 6000 solid dispersions. Drug Dev Ind Pharm 1985; 11:537-49.
136. Ford JL, Rubinstein MH. Formulation and aging of tablets prepared from indomethacin-poly(ethylene glycol) 6000 solid dispersions. Pharm Acta Helv 1980; 55:1-7.
137. Ford JL, Rubinstein MH. Preparation, properties and aging of tablets prepared from the chlorpropamide-urea solid dispersion. Int J Pharm 1981; 8:311-22.
138. Ravis WR, Chen CY. Dissolution, stability, and absorption characteristics of dicumarol in polyethylene glycol 4000 solid dispersions. J Pharm Sci 1981; 70:1353-57.
139. Ford JL, Rubinstein MH. Aging of indomethacin-poly(ethylene glycol) 6000 solid dispersions. Pharm Acta Helv 1979; 54:353-58.
140. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical system. J Pharm Sci 1997; 86:1-12.
141. Andronis V, Yoshioka M, Zografi G. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci 1997; 86:346-51.
142. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 1997; 14:1691-98.
143. Doherty C, York P. Evidence for solid- and liquid-state interactions in a furosemide-polyvinylpyrrolidone solid dispersion. J Pharm Sci 1987; 76:731-37.
144. Hancock BC, Shamblin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 1995; 12:799-806.
145. Ediger MD, Angell CA, Nagel SR. Supercooled liquids and glasses. J Phys Chem 1996; 100:13200-12.
146. Fukuoka E, Makita M, Yamamura S. Glassy state of pharmaceuticals. III. Thermal properties and stability of glassy pharmaceuticals and their binary glass systems. Chem Pharm Bull 1989; 37:1047-50.
147. Hamaura T, Newton JM. Interaction between water and poly(vinylpyrrolidone) containing polyethylene glycol. J Pharm Sci 1999; 88:1228-33.
148. Taylor LS, Zografi G. Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci 1998; 87:1615-21.
149. Perng CY, Kearney AS, Patel K, Palepu NR, Zuber G. Investigation of formulation approaches to improve the dissolution of SB-210661, a poorly water soluble 5-lipoxygenase inhibitor. Int J Pharm 1998; 176:31-38.
150. Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluids 2001; 20:179-219.
151. Matsumoto T, Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm Res 1999; 16:1722-28.
152. Forster A, Hempenstall J, Rades T. Characterisation of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol 2001; 53:57-66.
153. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv 1997; 23:3-25.
154. Lipinski CA. Avoiding investment in doomed drugs. Curr Drug Discov 2001; 1:17-19.